Flat year, new shape: H1 2026 activists took board seats by settlement, and started pricing AI

Shareholder activism in the first half of 2026 did not grow, it changed route: activity held steady at H1 2025 levels despite a fresh wave of market volatility, according to a memorandum from Antoinette Giblin, editorial manager at Diligent Market Intelligence ^[1][2]. DMI's finding that matters most for boards is procedural: settlements provided the only real path to the boardroom, with few fights going the whole way to a vote as boards and activists looked for common ground in uncertain markets ^[3].

The newer thesis is thinner but worth reading closely. DMI says AI found its place in the activist playbook, with key technology brands pressed on integration and cost rationalization ^[4]. The memo names no companies and gives no campaign count, so this is a signal rather than a tally. Note what the phrase couples, though: integration sits next to cost rationalization, which is a demand for evidence of return on spend rather than an argument about roadmap ambition. A board that cannot show what its AI budget has retired, automated or repriced is leaving that narrative to be written by someone with an 8% stake and a slate.

On deals, DMI reports M&A continued to build momentum as an activist lever, with many investors more willing to stand in the way of transactions they viewed as undervalued or poorly timed ^[5]. STAAR Surgical is the clearest case. Broadwood Capital, a 30% shareholder, led opposition to the medical device maker's combination with Swiss peer Alcon, a deal valued at around $1.5 billion when announced in August 2025 ^[6][7], arguing STAAR had "sufficient cash, strong demand, new products ready to be launched" ^[8]. Yunqi Capital and former CEO David Bailey came out against, with Defender Capital and CalSTRS following, and both ISS and Glass Lewis recommended against ^[9][10]. Broadwood moved on three directors by December ^[11], and after several postponements and a sweetened bid, the January 6 special meeting saw the sale collapse ^[12].

Lululemon is the settlement template. Founder and former CEO Chip Wilson, who started the company in 1998, owns around 8% of the shares and left the board in 2015, walked away from a proxy contest in May in exchange for two board seats ^{[13][14][15][16]}. His case was product, not capital: he argued the retailer was "losing its soul" through an alleged disinterest in product development, citing quality controversies around the ultra sheer "Get Low" leggings and a 2024 scandal over the Breeze through range design ^[17][18]. Before the deal was signed, Lululemon had already made leadership changes including naming Nike executive Heidi O'Neill as CEO, succeeding Calvin McDonald in September ^[19].

Warner Bros. Discovery shows where dissent goes when directors are not the target. Paramount Skydance beat Netflix with an all-cash bid that included the television channels Netflix planned to exclude ^[20]. Along the way, Pentwater Capital Management threatened to withhold support for directors if Warner failed to engage with Paramount, Paramount raised the prospect of a proxy fight and planned to solicit against the competing Netflix transaction, and Ancora Advisors said it was considering its own contest over Warner's lack of engagement ^[21][22][23]. The deal passed with overwhelming support on April 23, but the $1.4 billion golden parachute package was rejected with 82% opposition, and the remuneration plan drew 84% opposition at the June annual meeting ^[24][25][26], two percentage points worse ^[27].

Watch whether DMI's second-half data attaches named targets and specific asks to the AI thesis, and whether the settlement-first pattern survives a calmer market. Pay votes, meanwhile, remain the cheapest available protest for holders who have already conceded the strategic argument ^[26].